Drugs / SAIT101
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02819726 | Oct 2016 → Apr 2018 | rheumatoid arthritis | Archigen Biotech Limited | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT02809053 | Jan 2017 → Jul 2019 | follicular lymphoma | Archigen Biotech Limited | Completed | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SAIT101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02809053 ↗ |
| Route | Intravenous | “Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22” NCT02809053 ↗ |